Hypercalcemia of Malignancy: Simultaneous Elevation in Parathyroid Hormone-Related Peptide and 1,25 Dihydroxyvitamin D in Sarcoma
dc.contributor.author | Kim, Dong Won | |
dc.contributor.author | Miller, Ann | |
dc.contributor.author | Li, Andrew | |
dc.contributor.author | Hardy, Naomi | |
dc.contributor.author | Silver, Kristi D | |
dc.date.accessioned | 2021-06-09T18:29:25Z | |
dc.date.available | 2021-06-09T18:29:25Z | |
dc.date.issued | 2021-01-07 | |
dc.identifier.uri | http://hdl.handle.net/10713/15970 | |
dc.description.abstract | Hypercalcemia is a common finding in patients who have an underlying malignancy. Only a few cases of hypercalcemia of malignancy have been linked to more than one mechanism of hypercalcemia. Here, we present a patient with liposarcoma and hypercalcemia of malignancy in the setting of simultaneous elevations in parathyroid hormone-related peptide (PTHrP) and 1,25 dihydroxyvitamin D [1,25(OH)2D] levels. Sarcoma-associated hypercalcemia is a rare disorder. | en_US |
dc.description.uri | https://doi.org/10.1016/j.aace.2020.11.037 | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Inc. | en_US |
dc.relation.ispartof | AACE clinical case reports | en_US |
dc.rights | © 2021Published by Elsevier Inc. on behalf of the AACE. | en_US |
dc.subject | 1,25 dihydroxyvitamin D | en_US |
dc.subject | 1,25(OH)2D, 1,25 Dihydroxyvitamin D | en_US |
dc.subject | PTHrP | en_US |
dc.subject | PTHrP, parathyroid hormone-related peptide | en_US |
dc.subject | hypercalcemia of malignancy | en_US |
dc.subject | sarcoma | en_US |
dc.title | Hypercalcemia of Malignancy: Simultaneous Elevation in Parathyroid Hormone-Related Peptide and 1,25 Dihydroxyvitamin D in Sarcoma | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1016/j.aace.2020.11.037 | |
dc.identifier.pmid | 34095480 | |
dc.source.volume | 7 | |
dc.source.issue | 3 | |
dc.source.beginpage | 169 | |
dc.source.endpage | 173 | |
dc.source.country | United States |